Iterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual Meeting

HOUSTON, May 4, 2026 /PRNewswire/ — Iterion Therapeutics , a clinical-stage biopharmaceutical company developing novel therapies for Wnt/β-catenin-driven cancers, today announced that tegavivint, a first-in-class small-molecule inhibitor of TBL1, will be featured in three presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2 in Chicago.

The release as fetched from its publisher. iteriontherapeutics.com ↗